ArticleJCO clinical cancer informatics2025
Computational Morphological Assessment of Bladder Cancer Tissue Is Prognostic of Recurrence and Overall Survival Following Transurethral Resection.
Article in JCO clinical cancer informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An agentic framework for autonomous scientific discovery in cancer pathology.Nature medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeCurrent risk assessment tools for bladder cancer following transurethral resection of the bladder tumor (TURBT) depend on pathological examination of resected tissue, with the consequent intra- and inter-reviewer variability. Improved prognostic tools could enable increased monitoring and aggressive interventions for high-risk patients while reducing the frequency of invasive testing for low-risk patients.
methodsWe present an automated tumor risk assessment method based on quantitative features of nuclear pleomorphism and polarity extracted from digitized hematoxylin and eosin slides and compared this model with pathologist grading. Our model, incorporating six features, was trained to estimate overall survival risk on n = 189 patients and validated for recurrence prognosis on an independent validation set of n = 151 patients.
resultsThe model had an accuracy of 0.73 (95% CI, 0.66 to 0.81) in identifying patients who would have recurrence within 5 years of surgery. Within the validation set was a consensus set of patients (n = 94) on which three pathologists independently assigned the same grade and a nonconsensus set (n = 57) where they did not. The model had similar performance in the consensus and nonconsensus set, with accuracies of 0.70 (95% CI, 0.61 to 0.80) and 0.78 (95% CI, 0.67 to 0.89), respectively, and was able to recapitulate pathologist scoring on the consensus set (accuracy = 0.76).
conclusionThe results of this study suggest the need to incorporate both computerized analysis and pathologist grading into post-TURBT treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.